PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2129189
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2129189
Drug Repurposing Market Insights, Competitive Landscape, and Market Forecast - 2033
The drug repurposing market is witnessing steady growth, supported by lower development costs and faster regulatory pathways compared with novel drug development and rising demand across major end-use segments. Buyers are increasingly prioritizing measurable performance and reliable value over legacy alternatives, encouraging manufacturers to broaden their clinical and regulatory development initiatives. Continued advances in clinical and regulatory development are further improving product quality, consistency, and overall value for end users. The global drug repurposing market is expected to be valued at US$ 35.80 Bn in 2026 and is projected to reach US$ 47.75 Bn by 2033, growing at a CAGR of 4.2% between 2026 and 2033.
Market Insights:
The drug repurposing industry continues to evolve as manufacturers respond to shifting end-user requirements across Disease Area, Drug Type and End Use. Growing demand for differentiated, higher-performance solutions is encouraging investment in clinical and regulatory development, while buyers increasingly weigh total cost of ownership alongside upfront pricing when selecting suppliers. Manufacturers are also strengthening regional distribution and support capabilities to serve a broader and more diverse customer base, reinforcing the importance of technical credibility and responsive service in purchasing decisions.
Drivers:
Market growth is primarily supported by lower development costs and faster regulatory pathways compared with novel drug development, prompting sustained investment from established manufacturers as well as newer entrants. Buyers are placing greater emphasis on performance consistency, regulatory compliance, and lifecycle costs when evaluating suppliers, while continued product innovation is expanding the range of viable applications across Disease Area, Drug Type and End Use. Growing end-user awareness is translating into broader adoption across both established and emerging segments, reinforcing demand through the forecast period.
Business Opportunity:
The market presents meaningful opportunity tied to AI-assisted target identification and expanding oncology and rare-disease applications. Manufacturers that invest in clinical and regulatory development, expand regional capacity, and strengthen manufacturing and distribution are well positioned to capture additional share as demand broadens across end-use segments. Further opportunity exists in expanding service-based revenue streams, including maintenance, monitoring, and advisory offerings that complement core product or service sales.
Region Analysis:
North America and Europe remain significant contributors to the drug repurposing market, supported by established production and distribution bases, mature regulatory frameworks, and steady replacement and upgrade demand. East Asia and South Asia & Oceania together represent a major growth opportunity, underpinned by expanding capacity, rising end-user awareness, and increasing investment in local production and distribution infrastructure. Latin America and the Middle East & Africa are expected to contribute incremental growth over the forecast period, aided by infrastructure development, urbanization, and gradual expansion of formal distribution channels.
Key Players:
- Eli Lilly and Company
- Pfizer Inc.
- Roche Holding AG
- Novartis AG
- Bayer AG
- GSK plc
- Amgen Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Incorporated
Segmentation:
By Disease Area
- Oncology
- Neurology Disorders
- Infectious Diseases
- Cardiovascular Conditions
- Metabolic Disorders
- Others Therapeutic Areas
By Drug Type
- Conventional Small Molecules
- Biologics and Peptide-based Drugs
By End Use
- Biopharmaceutical & Pharmaceutical Companies
- Clinical Research Organizations (CROs)
- Universities & Research Institutions
By Regions
- North America
- Europe
- East Asia
- South Asia & Oceania
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Drug Repurposing Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Five Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
3. Global Drug Repurposing Market Outlook, 2020-2033
- 3.1. Global Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 3.1.1. Oncology
- 3.1.2. Neurology Disorders
- 3.1.3. Infectious Diseases
- 3.1.4. Cardiovascular Conditions
- 3.1.5. Metabolic Disorders
- 3.1.6. Others Therapeutic Areas
- 3.2. Global Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 3.2.1. Conventional Small Molecules
- 3.2.2. Biologics and Peptide-based Drugs
- 3.3. Global Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 3.3.1. Biopharmaceutical & Pharmaceutical Companies
- 3.3.2. Clinical Research Organizations (CROs)
- 3.3.3. Universities & Research Institutions
- 3.4. Global Drug Repurposing Market Outlook, by Region, Value (US$ Bn), 2020-2033
- 3.4.1. North America
- 3.4.2. Europe
- 3.4.3. Asia Pacific
- 3.4.4. Latin America
- 3.4.5. Middle East & Africa
4. North America Drug Repurposing Market Outlook, 2020-2033
- 4.1. North America Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 4.1.1. Oncology
- 4.1.2. Neurology Disorders
- 4.1.3. Infectious Diseases
- 4.1.4. Cardiovascular Conditions
- 4.1.5. Metabolic Disorders
- 4.1.6. Others Therapeutic Areas
- 4.2. North America Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 4.2.1. Conventional Small Molecules
- 4.2.2. Biologics and Peptide-based Drugs
- 4.3. North America Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 4.3.1. Biopharmaceutical & Pharmaceutical Companies
- 4.3.2. Clinical Research Organizations (CROs)
- 4.3.3. Universities & Research Institutions
- 4.4. North America Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 4.4.1. U.S. Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 4.4.2. U.S. Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 4.4.3. U.S. Drug Repurposing Market Outlook, by End Use, 2020-2033
- 4.4.4. Canada Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 4.4.5. Canada Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 4.4.6. Canada Drug Repurposing Market Outlook, by End Use, 2020-2033
- 4.5. BPS Analysis/Market Attractiveness Analysis
5. Europe Drug Repurposing Market Outlook, 2020-2033
- 5.1. Europe Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 5.1.1. Oncology
- 5.1.2. Neurology Disorders
- 5.1.3. Infectious Diseases
- 5.1.4. Cardiovascular Conditions
- 5.1.5. Metabolic Disorders
- 5.1.6. Others Therapeutic Areas
- 5.2. Europe Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 5.2.1. Conventional Small Molecules
- 5.2.2. Biologics and Peptide-based Drugs
- 5.3. Europe Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 5.3.1. Biopharmaceutical & Pharmaceutical Companies
- 5.3.2. Clinical Research Organizations (CROs)
- 5.3.3. Universities & Research Institutions
- 5.4. Europe Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 5.4.1. Germany Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.2. Germany Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.3. Germany Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.4. Italy Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.5. Italy Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.6. Italy Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.7. France Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.8. France Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.9. France Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.10. U.K. Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.11. U.K. Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.12. U.K. Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.13. Spain Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.14. Spain Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.15. Spain Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.16. Russia Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.17. Russia Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.18. Russia Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.4.19. Rest of Europe Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 5.4.20. Rest of Europe Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 5.4.21. Rest of Europe Drug Repurposing Market Outlook, by End Use, 2020-2033
- 5.5. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Drug Repurposing Market Outlook, 2020-2033
- 6.1. Asia Pacific Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 6.1.1. Oncology
- 6.1.2. Neurology Disorders
- 6.1.3. Infectious Diseases
- 6.1.4. Cardiovascular Conditions
- 6.1.5. Metabolic Disorders
- 6.1.6. Others Therapeutic Areas
- 6.2. Asia Pacific Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 6.2.1. Conventional Small Molecules
- 6.2.2. Biologics and Peptide-based Drugs
- 6.3. Asia Pacific Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 6.3.1. Biopharmaceutical & Pharmaceutical Companies
- 6.3.2. Clinical Research Organizations (CROs)
- 6.3.3. Universities & Research Institutions
- 6.4. Asia Pacific Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 6.4.1. China Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.2. China Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.3. China Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.4.4. Japan Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.5. Japan Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.6. Japan Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.4.7. South Korea Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.8. South Korea Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.9. South Korea Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.4.10. India Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.11. India Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.12. India Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.4.13. Southeast Asia Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.14. Southeast Asia Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.15. Southeast Asia Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.4.16. Rest of SAO Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 6.4.17. Rest of SAO Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 6.4.18. Rest of SAO Drug Repurposing Market Outlook, by End Use, 2020-2033
- 6.5. BPS Analysis/Market Attractiveness Analysis
7. Latin America Drug Repurposing Market Outlook, 2020-2033
- 7.1. Latin America Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 7.1.1. Oncology
- 7.1.2. Neurology Disorders
- 7.1.3. Infectious Diseases
- 7.1.4. Cardiovascular Conditions
- 7.1.5. Metabolic Disorders
- 7.1.6. Others Therapeutic Areas
- 7.2. Latin America Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 7.2.1. Conventional Small Molecules
- 7.2.2. Biologics and Peptide-based Drugs
- 7.3. Latin America Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 7.3.1. Biopharmaceutical & Pharmaceutical Companies
- 7.3.2. Clinical Research Organizations (CROs)
- 7.3.3. Universities & Research Institutions
- 7.4. Latin America Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 7.4.1. Brazil Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 7.4.2. Brazil Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 7.4.3. Brazil Drug Repurposing Market Outlook, by End Use, 2020-2033
- 7.4.4. Mexico Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 7.4.5. Mexico Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 7.4.6. Mexico Drug Repurposing Market Outlook, by End Use, 2020-2033
- 7.4.7. Argentina Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 7.4.8. Argentina Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 7.4.9. Argentina Drug Repurposing Market Outlook, by End Use, 2020-2033
- 7.4.10. Rest of LATAM Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 7.4.11. Rest of LATAM Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 7.4.12. Rest of LATAM Drug Repurposing Market Outlook, by End Use, 2020-2033
- 7.5. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Drug Repurposing Market Outlook, 2020-2033
- 8.1. Middle East & Africa Drug Repurposing Market Outlook, by Disease Area, Value (US$ Bn), 2020-2033
- 8.1.1. Oncology
- 8.1.2. Neurology Disorders
- 8.1.3. Infectious Diseases
- 8.1.4. Cardiovascular Conditions
- 8.1.5. Metabolic Disorders
- 8.1.6. Others Therapeutic Areas
- 8.2. Middle East & Africa Drug Repurposing Market Outlook, by Drug Type, Value (US$ Bn), 2020-2033
- 8.2.1. Conventional Small Molecules
- 8.2.2. Biologics and Peptide-based Drugs
- 8.3. Middle East & Africa Drug Repurposing Market Outlook, by End Use, Value (US$ Bn), 2020-2033
- 8.3.1. Biopharmaceutical & Pharmaceutical Companies
- 8.3.2. Clinical Research Organizations (CROs)
- 8.3.3. Universities & Research Institutions
- 8.4. Middle East & Africa Drug Repurposing Market Outlook, by Country, Value (US$ Bn), 2020-2033
- 8.4.1. GCC Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 8.4.2. GCC Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 8.4.3. GCC Drug Repurposing Market Outlook, by End Use, 2020-2033
- 8.4.4. South Africa Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 8.4.5. South Africa Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 8.4.6. South Africa Drug Repurposing Market Outlook, by End Use, 2020-2033
- 8.4.7. Egypt Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 8.4.8. Egypt Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 8.4.9. Egypt Drug Repurposing Market Outlook, by End Use, 2020-2033
- 8.4.10. Nigeria Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 8.4.11. Nigeria Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 8.4.12. Nigeria Drug Repurposing Market Outlook, by End Use, 2020-2033
- 8.4.13. Rest of Middle East Drug Repurposing Market Outlook, by Disease Area, 2020-2033
- 8.4.14. Rest of Middle East Drug Repurposing Market Outlook, by Drug Type, 2020-2033
- 8.4.15. Rest of Middle East Drug Repurposing Market Outlook, by End Use, 2020-2033
- 8.5. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Eli Lilly and Company
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Pfizer Inc.
- 9.4.3. Roche Holding AG
- 9.4.4. Novartis AG
- 9.4.5. Bayer AG
- 9.4.6. GSK plc
- 9.4.7. Amgen Inc.
- 9.4.8. Biogen Inc.
- 9.4.9. Teva Pharmaceutical Industries Ltd.
- 9.4.10. Vertex Pharmaceuticals Incorporated
- 9.4.1. Eli Lilly and Company
10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
